Cullinan Therapeutics, Inc.
For the period ended Sep 30, 2026. Filed Nov 10, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 10, 2026
CGEM$11.23-4.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(in thousands, except share amounts)
| September 30, 2026 | December 31, 2025 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $88,260 | $88,332 |
| Short-term investments | 201,313 | 289,564 |
| Prepaid expenses and other current assets | 8,580 | 8,860 |
| Total current assets | 298,153 | 386,756 |
| Property and equipment, net | 210 | 421 |
| Operating lease right-of-use assets | 1,996 | 2,630 |
| Other assets | 297 | 297 |
| Long-term investments | 21,903 | 58,270 |
| Total assets | $322,559 | $448,374 |
| Liabilities and Stockholders' Equity | ||
| Current liabilities: | ||
| Accounts payable | $1,135 | $841 |
| Accrued expenses and other current liabilities | 38,136 | 36,120 |
| Operating lease liabilities, current | 859 | 780 |
| Total current liabilities | 40,130 | 37,741 |
| Operating lease liabilities, net of current portion | 1,145 | 1,903 |
| Total liabilities | 41,275 | 39,644 |
| Commitments and contingencies (Note 8) | ||
| Stockholders' equity: | ||
| Preferred stock, $0.0001 par value, 10,000,000 shares authorized as of September 30, 2026 and December 31, 2025; 161,094 and 555,935 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively | — | — |
| Common stock, $0.0001 par value, 150,000,000 shares authorized as of September 30, 2026 and December 31, 2025; 64,900,924 and 60,244,136 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively | 6 | 6 |
| Additional paid-in capital | 1,022,802 | 995,823 |
| Accumulated other comprehensive income (loss) | (652) | 1,020 |
| Accumulated deficit | (740,872) | (588,119) |
| Total stockholders' equity | 281,284 | 408,730 |
| Total liabilities and stockholders' equity | $322,559 | $448,374 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.